Perindopril vs Ramipril for Persistence in MAU Reduction Study

Launched by SUNNYBROOK HEALTH SCIENCES CENTRE · Mar 31, 2016

Keywords

ClinConnect Summary

Design/Method This was a single arm, prospective, randomized, single blinded, open label cross-over study of the urine albumin excretion during the day and at night after 12 weeks of therapy with either perindopril 8 mg per day or ramipril 10 mg per day in people with diabetes. Men and women were eligible for the study if they met the following criteria: Age\>18 years, type 2 diabetes with adequate blood sugar control (Hemoglobin A1c (A1c)\<8.4%), therapy with ace inhibitor(ACEi) or angiotensin receptor blocker (ARB) for a period of 8 weeks prior to and throughout the screening period along...

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Type 2 Diabetes,
• • stable therapy with an ACEi or ARB for 8 weeks prior to screening period
• • blood pressure controlled to \< 130/80 mmHg
• Exclusion Criteria:
• • Pregnancy,
• • dual therapy with ACEi and ARB 8 weeks prior to screening
• • history of cough with ACEi
• • hypersensitivity to either medication
• • myocardial infarction within 12 weeks of screening
• • congestive heart failure (NYHA Class IV)
• • severe coronary artery disease
• • severe liver disease
• • renal artery stenosis.